Fiche centre
Valkyrie Clinical Trials
Los Angeles — United States
Essais liés5clinical trials
VilleLos Angeleslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07659782
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| INBRX-106 - Hexavalent OX40 agonist antibody | Cancer | Phase 1/2 | NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING |
| VS-7375 | Cancer | Phase 2 | NCT07659782 | TARGET-D 202 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | RECRUITING |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |
| Elranatamab | Cancer | Phase 3 | NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING |
| Obinutuzumab | Cancer | Phase 2 | NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | RECRUITING |